Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Coronavirus: invasive/novel

Generalities
Agent Coronaviruses belong to a large family of viruses that can cause diseases ranging from the common cold to Severe Acute Respiratory Syndrome (SARS).
1) Classical coronavirus: viruses that can infect humans and animals.
- Human coronavirus (HCoV): causing mild illness (229E, OC43, NL63, and HKU1...)
- Animal coronavirus: may infect pigs, domestic and wild birds, bats, rodents, dogs, cats and cattle. They cause acute and chronic diseases in animals such as respiratory and gastro-enteric diseases, neurologic diseases, and liver disease.
2) Novel coronavirus:
- Severe Acute Respiratory Syndrome (SARS-CoV) who caused a large outbreak in 2002-2003.
- Middle East respiratory syndrome–Novel Coronavirus (MERS-CoV): first identified in 2012
- Novel Coronavirus 2019 (COVID-19)
Incubation period - HCoV: 2-4 days
- SARS-CoV: 2-10 days (mean; 5 days)
- MERS-CoV: 2-14 days
- COVID-19: 4-7 days (up to 14 days)
Period of transmissibility - HCoV: during the active disease
- SARS-CoV: from onset to 21 days
- MERS-CoV: during illness. The duration of infectivity after resolution of symptoms is unknown.
- COVID-19: usually during illness
Reservoir - HCoV: Humans
- SARS-CoV: cave-dwelling bats (genus Rhinolophus), Himalayan masked palm civet (Paguma larvata), other wildlife animals
- MERS-CoV: may be camels and bats
Modes of transmission - HCoV: person-to-person transmission via repiratory droplets, aerosls, fecal oral route, fomites
- SARS-CoV: 1) Animal-to-person; 2) Person-to-person: while caring for, or living with a patient; via respiratory secretions, via body fluids; or airborne (aerosolized sewage, mechanical ventilation...)
- MERS-CoV: 1) Limited person-to-person transmission: close contact, when providing unprotected care to a patient; 2) Suspected animal-to-person transmission via droplet contact, fomite transmission, food-borne, airbone
- COVID-19: 1) Person-to-person: droplets (directly or indirectly), aerosol generating medical procedures, 2) Animal-to-peron
Clinical presentation - HCoV: usually self-limited illness as upper respiratory infection, otitis media, gastroenteritis. Complications: pneumonia, encephalitis, peritonitis...
- SARS-CoV: pneumonia, acute respiratory distress syndrome (ARDS). Global case fatality in 2003: 10%.
- MERS-CoV: usually, acute lower respiratory infection with or without gastrointestinal symptoms. It may be asymptomatic. The illness may be severe in people with chronic medical conditions. It may evolve to respiratory failure, organ failure (as renal failure), septic shock... Global case fatality: 27%.
- COVID-19: usually acute respiratory infection
Resources
Case definition - MOPH circular no. 35 (2012): SARS-CoV
- MOPH circular no. 37 (2014): MERS-CoV
- MOPH circular no. 42 (2020): COVID-19
Forms - General reporting form
- Novel Coronavirus reporting form
- Laboratory request form
- Patient transfert request form
- SARS-CoV investigation form
- MERS-CoV investigation form
Data - SARS-CoV: No SARS-CoV was detected in Lebanon in 2003
- MERS-CoV: 2 cases detected and confirmed in 2014 and 2017
- COVID-19: Daily report on COVID-19
Other Resources - Specimen collection for COVID-19
- Questions and Answers
- Presentation: coronavirus, A, E
- Presentation: resources, A, E
- Presentation: questions and answers, A, E
- Presentation: case definition, A, E
- Presentation: specimen collection, A, E
- Presentation: areas with community transmission, A, E
    ...
    142
    ...
ATC Name B/G Ingredients Dosage Form Price
C09CA03 VIOSTAN 80 G Valsartan - 80mg 80mg Tablet, film coated 526,786 L.L
C10AA05 ATORLIP 40 G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 1,484,626 L.L
G04BE08 HEROX G Tadalafil - 5mg 5mg Tablet, film coated 1,416,410 L.L
L01EK01 INLYTA B Axitinib - 1mg 1mg Tablet, film coated 57,595,789 L.L
C09CA03 DIOVAN B Valsartan - 160mg 160mg Tablet, film coated 846,621 L.L
C10AA05 ATORVA TAD G Atorvastatin - 40mg 40mg Tablet, film coated 1,405,659 L.L
G04BE08 LINK G Tadalafil - 5mg 5mg Tablet, film coated 3,926,708 L.L
L01EL01 IMBRUVICA B Ibrutinib - 140mg 140mg Tablet, film coated 187,342,573 L.L
C09CA03 ANGINET G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
L04AA29 TRIJAN G Tofacitinib - 5mg 5mg Tablet, film coated 54,863,315 L.L
J01MA12 FLOBIOX G Levofloxacin - 500mg 500mg Tablet, film coated 629,686 L.L
L01EL01 IMBRUVICA B Ibrutinib - 420mg 420mg Tablet, film coated 562,026,556 L.L
C09CA03 TABUVAN G Valsartan - 160mg 160mg Tablet, film coated 544,256 L.L
C10AA05 EMITOR G Atorvastatin - 40mg 40mg Tablet, film coated 1,060,292 L.L
G04BE08 TADALAGEN G Tadalafil - 5mg 5mg Tablet, film coated 1,766,193 L.L
J01MA12 FLOBIOX G Levofloxacin - 500mg 500mg Tablet, film coated 794,787 L.L
L04AA29 TRIJAN G Tofacitinib - 10mg 10mg Tablet, film coated 84,793,962 L.L
C09CA03 VALSANET G Valsartan - 160mg 160mg Tablet, film coated 560,574 L.L
G04BE08 TADILAS G Tadalafil - 5mg 5mg Tablet, film coated 1,583,046 L.L
J01DB05 BIODROXIL G Cefadroxil (monohydrate) - 1000mg 1,000mg Tablet, film coated 1,049,867 L.L
J01MA12 FLOXIN-L 500 G Levofloxacin (hemihydrate) - 500mg 500mg Tablet, film coated 831,903 L.L
L01EM03 PIQRAY B Alpelisib - 150mg 150mg Tablet, film coated 359,195,954 L.L
L04AA31 AUBAGIO B Teriflunomide - 14mg 14mg Tablet, film coated 38,773,533 L.L
N02BE01 EFFERALGAN B Paracetamol - 1g 1g Tablet, film coated 129,009 L.L
C10AA05 LIPODAR G Atorvastatin (calcium) - 40mg 40mg Tablet, film coated 2,412,197 L.L
G04BE08 TALYS G Tadalafil - 5mg 5mg Tablet, film coated 1,574,216 L.L
J01MA12 JOSWE AVOXIN 500 G Levofloxacin - 500mg 500mg Tablet, film coated 786,148 L.L
L01EM03 PIQRAY B Alpelisib - 200mg, Alpelisib - 50mg 150mg Tablet, film coated 359,195,954 L.L
L04AA31 AUBAGIO B Teriflunomide - 14mg 14mg Tablet, film coated 38,773,533 L.L
C09CA03 VALUSTAR G Valsartan - 160mg 160mg Tablet, film coated 634,294 L.L
    ...
    142
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025